Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Arterial Diseases | Research

Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study

Authors: Yanan Cui, Zijie Zhan, Yiming Ma, Ke Huang, Chen Liang, Xihua Mao, Yaowen Zhang, Xiaoxia Ren, Jieping Lei, Yan Chen, Ting Yang, Chen Wang

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Coronary artery disease (CAD) is a common comorbidity of chronic obstructive pulmonary disease (COPD). However, data related to the impact of CAD on outcomes of acute exacerbation of COPD (AECOPD) are limited and whether the relationship depends on sex remains unknown. Our aim was to determine the impact of comorbid CAD on clinical outcomes among men and women with AECOPD.

Methods

We used data from the acute exacerbation of chronic obstructive pulmonary disease inpatient registry (ACURE) study, which is a nationwide observational real-world study conducted between September 2017 and February 2020 at 163 centers in patients admitted with AECOPD as their primary diagnosis. Patients were stratified according to the presence or absence of CAD in men and women. The primary outcomes were the length of hospital stay and economic burden during hospitalization.

Results

Among 3906 patients included in our study, the prevalence of CAD was 17.0%, and it was higher in women than in men (19.5% vs. 16.3%; P = 0.034). Age and other cardiovascular diseases were common factors associated with comorbid CAD in men and women, while body-mass index, cerebrovascular disease, and diabetes were determinants in men and pre-admission use of long-acting beta-adrenoceptor agonist and home oxygen therapy were protective factors in women. Only in men, patients with CAD had a longer length of hospital stay (median 10.0 vs. 9.0 days, P < 0.001), higher total cost during hospitalization (median $1502.2 vs. $1373.4, P < 0.001), and more severe COPD symptoms at day 30 compared to those without CAD. No significant difference was found in women. Comorbid CAD showed no relationship with 30-day readmission or death regardless of sex. In our real-world study, mortality/readmission risk within 30 days increased in patients with previous frequent hospitalizations and poorer pulmonary function.

Conclusions

In hospitalized AECOPD patients, comorbid CAD was significantly associated with poorer short-term outcomes in men. Clinicians should have heightened attention for men with comorbid CAD to achieve an optimal management of AECOPD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Committee GE. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2021 REPORT). http://goldcopd.com. Accessed Nov 2020. Committee GE. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2021 REPORT). http://​goldcopd.​com. Accessed Nov 2020.
2.
go back to reference Leong P, Bardin PG. The untreated treatable trait: cardiovascular disease in COPD exacerbations. Respirology. 2021;26(5):413–5.CrossRef Leong P, Bardin PG. The untreated treatable trait: cardiovascular disease in COPD exacerbations. Respirology. 2021;26(5):413–5.CrossRef
3.
go back to reference Lee HM, Liu MA, Barrett-Connor E, Wong ND. Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: the Rancho Bernardo study. Respir Med. 2014;108(12):1779–85.CrossRef Lee HM, Liu MA, Barrett-Connor E, Wong ND. Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: the Rancho Bernardo study. Respir Med. 2014;108(12):1779–85.CrossRef
4.
go back to reference Yangui F, Touil A, Antit S, Zakhama L, Charfi MR. COPD prevalence in smokers with stable ischemic heart disease: a cross-sectional study in Tunisia. Respir Med. 2021;179:106335.CrossRef Yangui F, Touil A, Antit S, Zakhama L, Charfi MR. COPD prevalence in smokers with stable ischemic heart disease: a cross-sectional study in Tunisia. Respir Med. 2021;179:106335.CrossRef
5.
go back to reference Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851–7.CrossRef Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest. 2012;141(4):851–7.CrossRef
6.
go back to reference Rysiak E, Prokop I, Zaręba I, Mróz RM. Estimates of medication expenditure for ischemic heart disease accompanying chronic obstructive pulmonary disease. Adv Exp Med Biol. 2018;1114:49–55.CrossRef Rysiak E, Prokop I, Zaręba I, Mróz RM. Estimates of medication expenditure for ischemic heart disease accompanying chronic obstructive pulmonary disease. Adv Exp Med Biol. 2018;1114:49–55.CrossRef
7.
go back to reference Aliyali M, Mehravaran H, Abedi S, Sharifpour A, Yazdani CJ. Impact of comorbid ischemic heart disease on short-term outcomes of patients hospitalized for acute exacerbations of COPD. Tanaffos. 2015;14(3):165–71.PubMedPubMedCentral Aliyali M, Mehravaran H, Abedi S, Sharifpour A, Yazdani CJ. Impact of comorbid ischemic heart disease on short-term outcomes of patients hospitalized for acute exacerbations of COPD. Tanaffos. 2015;14(3):165–71.PubMedPubMedCentral
8.
go back to reference Trudzinski FC, Kellerer C, Jörres RA, Alter P, Lutter JI, Trinkmann F, et al. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clin Res Cardiol. 2021; Trudzinski FC, Kellerer C, Jörres RA, Alter P, Lutter JI, Trinkmann F, et al. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clin Res Cardiol. 2021;
9.
go back to reference Sánchez-Muñoz G, Lopez-de-Andrés A, Hernández-Barrera V, Jiménez-García R, Pedraza-Serrano F, Puente-Maestu L, et al. Bronchiectasis in patients hospitalized with acute exacerbation of COPD in Spain: influence on mortality, hospital stay, and hospital costs (2006–2014) according to gender. PLoS ONE. 2019;14(1):e0211222.CrossRef Sánchez-Muñoz G, Lopez-de-Andrés A, Hernández-Barrera V, Jiménez-García R, Pedraza-Serrano F, Puente-Maestu L, et al. Bronchiectasis in patients hospitalized with acute exacerbation of COPD in Spain: influence on mortality, hospital stay, and hospital costs (2006–2014) according to gender. PLoS ONE. 2019;14(1):e0211222.CrossRef
10.
go back to reference Choi HS, Rhee CK, Park YB, Yoo KH, Lim SY. Metabolic syndrome in early chronic obstructive pulmonary disease: gender differences and impact on exacerbation and medical costs. Int J Chron Obstruct Pulmon Dis. 2019;14:2873–83.CrossRef Choi HS, Rhee CK, Park YB, Yoo KH, Lim SY. Metabolic syndrome in early chronic obstructive pulmonary disease: gender differences and impact on exacerbation and medical costs. Int J Chron Obstruct Pulmon Dis. 2019;14:2873–83.CrossRef
11.
go back to reference Almagro P, López García F, Cabrera FJ, Montero L, Morchón D, Díez J, et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir Med. 2010;104(2):253–9.CrossRef Almagro P, López García F, Cabrera FJ, Montero L, Morchón D, Díez J, et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir Med. 2010;104(2):253–9.CrossRef
12.
go back to reference Cui H, Miao DM, Wei ZM, Cai JF, Li Y, Liu AM, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol. 2012;9(1):5–10.CrossRef Cui H, Miao DM, Wei ZM, Cai JF, Li Y, Liu AM, et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol. 2012;9(1):5–10.CrossRef
13.
go back to reference Pei Z, Sun Y, Wang S, Chen Y, Yang T, Huang K, et al. Estimating mortality among inpatients with acute exacerbation of chronic obstructive pulmonary disease using registry data. NPJ Prim Care Respir Med. 2020;30(1):28.CrossRef Pei Z, Sun Y, Wang S, Chen Y, Yang T, Huang K, et al. Estimating mortality among inpatients with acute exacerbation of chronic obstructive pulmonary disease using registry data. NPJ Prim Care Respir Med. 2020;30(1):28.CrossRef
14.
go back to reference Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRef
15.
go back to reference Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-426.PubMed Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344-426.PubMed
16.
go back to reference Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRef Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.CrossRef
17.
go back to reference Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387–96.CrossRef Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387–96.CrossRef
18.
go back to reference Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.CrossRef Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.CrossRef
19.
go back to reference Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–7.CrossRef Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–7.CrossRef
20.
go back to reference Bellocchia M, Masoero M, Ciuffreda A, Croce S, Vaudano A, Torchio R, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013;8(1):58.CrossRef Bellocchia M, Masoero M, Ciuffreda A, Croce S, Vaudano A, Torchio R, et al. Predictors of cardiovascular disease in asthma and chronic obstructive pulmonary disease. Multidiscip Respir Med. 2013;8(1):58.CrossRef
21.
go back to reference Crisan L, Wong N, Sin DD, Lee HM. Karma of cardiovascular disease risk factors for prevention and management of major cardiovascular events in the context of acute exacerbations of chronic obstructive pulmonary disease. Front Cardiovasc Med. 2019;6:79.CrossRef Crisan L, Wong N, Sin DD, Lee HM. Karma of cardiovascular disease risk factors for prevention and management of major cardiovascular events in the context of acute exacerbations of chronic obstructive pulmonary disease. Front Cardiovasc Med. 2019;6:79.CrossRef
22.
go back to reference Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–26.CrossRef Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–26.CrossRef
23.
go back to reference Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–25.CrossRef Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–25.CrossRef
24.
go back to reference Santus P, Radovanovic D, Di Marco S, Valenti V, Raccanelli R, Blasi F, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–23.CrossRef Santus P, Radovanovic D, Di Marco S, Valenti V, Raccanelli R, Blasi F, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015;10:1917–23.CrossRef
25.
go back to reference Cazzola M, Mantero A, Santus P, Carlucci P, Mondoni M, Bosotti L, et al. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther. 2007;20(3):258–64.CrossRef Cazzola M, Mantero A, Santus P, Carlucci P, Mondoni M, Bosotti L, et al. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther. 2007;20(3):258–64.CrossRef
26.
go back to reference Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1(1):Cd010139.PubMed Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1(1):Cd010139.PubMed
27.
go back to reference Kheir F, Salerno DA. Brain natriuretic peptide measurement in patients with COPD and cardiovascular disease. Chest. 2013;144(3):1081.CrossRef Kheir F, Salerno DA. Brain natriuretic peptide measurement in patients with COPD and cardiovascular disease. Chest. 2013;144(3):1081.CrossRef
28.
go back to reference Jafar Z, Valero-Elizondo J, Saeed GJ, Acquah I, Yahya T, Mahajan S, et al. Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2020;3:100084.CrossRef Jafar Z, Valero-Elizondo J, Saeed GJ, Acquah I, Yahya T, Mahajan S, et al. Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2020;3:100084.CrossRef
29.
go back to reference Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45(1):51–9.CrossRef Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45(1):51–9.CrossRef
30.
go back to reference Jones PW, Mullerova H, Agusti A, Decramer M, Adamek L, Raillard A, et al. Cardiovascular disease does not predict exacerbation rate or mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(3):400–3.CrossRef Jones PW, Mullerova H, Agusti A, Decramer M, Adamek L, Raillard A, et al. Cardiovascular disease does not predict exacerbation rate or mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(3):400–3.CrossRef
31.
go back to reference Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.CrossRef Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.CrossRef
32.
go back to reference Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–52.CrossRef Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–52.CrossRef
33.
go back to reference Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. Expert Rev Clin Pharmacol. 2021;14(3):323–32.CrossRef Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. Expert Rev Clin Pharmacol. 2021;14(3):323–32.CrossRef
34.
go back to reference Bhallamudi S, Connell J, Pabelick CM, Prakash YS, Sathish V. Estrogen receptors differentially regulate intracellular calcium handling in human nonasthmatic and asthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(1):L112–24.CrossRef Bhallamudi S, Connell J, Pabelick CM, Prakash YS, Sathish V. Estrogen receptors differentially regulate intracellular calcium handling in human nonasthmatic and asthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(1):L112–24.CrossRef
35.
go back to reference Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8(1):33.CrossRef Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8(1):33.CrossRef
Metadata
Title
Clinical and economic burden of comorbid coronary artery disease in patients with acute exacerbation of chronic obstructive pulmonary disease: sex differences in a nationwide cohort study
Authors
Yanan Cui
Zijie Zhan
Yiming Ma
Ke Huang
Chen Liang
Xihua Mao
Yaowen Zhang
Xiaoxia Ren
Jieping Lei
Yan Chen
Ting Yang
Chen Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-01945-7

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue